Tag - RIGL

Developments

Rigel Pharma enrolls first patients in Phase 2 COVID-19 trial

Rigel Pharmaceuticals (NASDAQ:RIGL) enrolled the first patients in its Phase 2 trial evaluating fostamatinib for the treatment of hospitalized COVID-19 patients. The study is sponsored by the NIH’s National Heart, Lung...

October 9, 2020

Developments

Rigel Pharma fostamatinib being evaluated in COVID-19 pneumonia trial

Rigel Pharmaceuticals’ (NASDAQ:RIGL) fostamatinib is being evaluated in an investigator-sponsored study for the treatment of COVID-19 pneumonia. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, is approved...

July 14, 2020

Developments

Rigel Pharma in pact with Grifols to commercialize fostamatinib in Europe

Rigel Pharmaceuticals (NASDAQ:RIGL) entered an exclusive license and supply agreement with Grifols (MCE:GRF; MCE:GRF.P; NASDAQ:GRFS) of Spain to commercialize fostamatinib disodium hexahydrate in all potential...

January 23, 2019

Executive Moves

Rigel Pharma names Dean Schorno as EVP and CFO

Rigel Pharmaceuticals (NASDAQ:RIGL) appointed Dean Schorno as EVP and CFO.

May 30, 2018

Tag - RIGL

Rigel Pharma enrolls first patients in Phase 2 COVID-19 trial

Rigel Pharma fostamatinib being evaluated in COVID-19 pneumonia trial

Rigel Pharma in pact with Grifols to commercialize fostamatinib in Europe

Rigel Pharma names Dean Schorno as EVP and CFO

General

More